Advertisement

Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine

  • Giuseppe BoccadifuocoEmail author
  • Brunella Brunelli
  • Elena Mori
  • Mauro Agnusdei
  • Claudia Gianfaldoni
  • Marzia Monica Giuliani
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1969)

Abstract

Meningococcal Antigen Typing System (MATS) is the combination of a sandwich ELISA (Enzyme Linked Immunosorbent Assay) developed to estimate the level of expression and immunoreactivity of the antigen components (fHbp, NHBA, and NadA) of the 4CMenB vaccine (Bexsero, GSK Vaccines) in circulating, serogroup B meningococcal (MenB) strains, with the molecular typing of PorA, the main antigenic component in the outer membrane vesicles (OMV). MATS has been proven to be a good surrogate of the accepted correlate of protection for meningococcus (hSBA), thus providing a quick, conservative and reproducible method to assess vaccine coverage. The method has been successfully transferred and standardized in several public health laboratories across Europe, North America, and Australia and used to screen thousands of isolates all over the world. Here we describe the sandwich ELISA method applied to assess the expression and cross-reactivity of fHbp, NHBA, and NadA in MenB isolates.

Key words

Vaccine Neisseria meningitidis Antibodies Coverage Meningococcal Antigen Typing System (MATS) ELISA Serum Bactericidal Assay (SBA) 

Notes

Acknowledgments, Sponsorship, and Conflict of Interest

Material and support for this study were provided by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in analysis and interpretation of data. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of the manuscript for factual accuracy, but we are solely responsible for final content and interpretation. We received no financial support or other form of compensation related to the development of the manuscript.

G.B., B.B., E.M., C.G., M.A., and M.M.G. are currently employed by the GSK group of companies.

G.B., B.B., E.M., C.G., M.A., and M.M.G. participated in the drafting and revision of the manuscript.

This is a methodology description, no data are included in this publication.

This work was sponsored by Novartis Vaccines and Diagnostics Srl; in March 2015 the Novartis non-influenza Vaccines business was acquired by the GSK group of companies. The sponsor was involved in all stages of the study conduct and analysis.

References

  1. 1.
    Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369:2196–2210CrossRefGoogle Scholar
  2. 2.
    Martin NG, Snape MD (2013) A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Exp Rev Vacc 12:837–858CrossRefGoogle Scholar
  3. 3.
    Wise J (2016) MenB vaccine programme cuts cases of meningitis and septicaemia in infants. BMJ 354:i4839CrossRefGoogle Scholar
  4. 4.
    Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R (2012) The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30(2):B87–B97CrossRefGoogle Scholar
  5. 5.
    Frasch CE, Borrow R, Donnelly J (2009) Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl 2):B112–B116CrossRefGoogle Scholar
  6. 6.
    Donnelly J, Medini D, Boccadifuoco G et al (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 107(45):19490–19495CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Giuseppe Boccadifuoco
    • 1
    Email author
  • Brunella Brunelli
    • 1
  • Elena Mori
    • 1
  • Mauro Agnusdei
    • 1
  • Claudia Gianfaldoni
    • 1
  • Marzia Monica Giuliani
    • 1
  1. 1.GSK VaccinesSienaItaly

Personalised recommendations